San Francisco Chronicle - (Sunday)
Chinese vaccines poised to fill key gap in supply line
TAIPEI, Taiwan — With rich countries snapping up supplies of COVID19 vaccines, some parts of the world may have to rely on Chinesedeveloped shots to try to conquer the outbreak. The question: Will they work?
There is no outward reason to believe they won’t, but China has a history of vaccine scandals, and its drugmakers have revealed little about their final human trials and the more than 1 million emergencyuse inoculations they say have been carried out inside the country already.
Wealthy nations have reserved about 9 billion of the 12 billion mostly Westerndeveloped shots expected to be produced next year, while COVAX, a global effort to ensure equal access to COVID19 vaccines, has fallen short of its promised capacity of 2 billion doses.
For those countries that have not yet secured a vaccine, China may be the only solution.
China has six candidates in the last stage of trials and is one of the few nations that can manufacture vaccine on a large scale. Government officials have announced a capacity of 1 billion doses next year, with President Xi Jinping vowing China’s vaccines will be a boon to the world.
The potential use of its vaccine by millions of people in other countries gives China an opportunity both to repair the damage to its reputation from an outbreak that escaped its borders and to show the world it can be a major scientific player.
Yet past scandals have damaged its own citizens’ trust in its vaccines, with manufacturing and supply chain problems casting doubt on whether it can really be a savior.
“A question mark remains over how China can ensure the delivery of reliable vaccines,” said Joy Zhang, a professor who studies the ethics of emerging science at the University of Kent in Britain. She cited China’s “nontransparency over scientific data and a troubled history with vaccine delivery.”
Bahrain recently became the second country to approve a Chinese COVID19 vaccine, joining the United Arab Emirates. Morocco plans to use Chinese vaccines in a mass immunization campaign. Chinese
vaccines are also awaiting approval in Turkey, Indonesia and Brazil, while testing continues in more than a dozen countries, including Russia, Egypt and Mexico.
In some countries, Chinese vaccines are viewed with suspicion. Brazil’s President Jair Bolsonaro has repeatedly sown doubt about the effectiveness of Chinese company Sinovac’s vaccine candidate without citing any evidence, and said Brazilians won’t be used as “guinea pigs.”
But many experts praise China’s vaccine capabilities.
“The studies look to be well done,” said Jamie Triccas, head of immunology and infectious diseases at the University of Sydney’s medical school, referring to clinical trial results published in scientific journals.
“I wouldn’t be overly concerned about that.”
China has been building up its immunization programs for more than a decade. It has produced successful vaccines on a large scale for its own population, including vaccinations for measles and hepatitis, said Jin Dongyan, a medical professor at the University of Hong Kong.
“There are no major outbreaks in China for any of these diseases,” he said. “That means the vaccines are safe and effective.”
China has worked with the Gates Foundation and others to improve manufacturing quality in the past decade. The World Health Organization has prequalified five nonCOVID19 Chinese vaccines, which allows U. N. agencies to buy them for other countries. The companies whose products won prequalification include Sinovac and stateowned Sinopharm, both leading developers of COVID19 vaccines.
China revised its laws in 2017 and 2019 to tighten management of vaccine storage and step up inspections and penalties for faulty vaccines.
The country’s major COVID19 vaccine developers have published some scientific findings in peerreviewed scientific journals. But experts questioned how China recruited volunteers and what kind of tracking there was for possible side effects. Chinese companies and government officials haven’t released details.